首页良性前列腺增生治疗及预后证据详情

First- and Second-Generation Temporary Implantable Nitinol Devices As Minimally Invasive Treatments for BPH-Related LUTS: Systematic Review of the Literature

原文:2019年 发布于 Current Urology Reports 20卷 第8期 浏览量:768次 原文链接
文献简介

IntroductionIn the last decade, there has been a growing interest in minimally invasive treatment for benign prostatic hyperplasia (BPH) associated with lower urinary tract symptoms (LUTS). In this field, one of the options currently available is the temporary implantable nitinol device (iTIND) (Medi-Tate (R); Medi-Tate Ltd., Or Akiva, Israel).Purpose of the WorkTo review the recent data available in the literature regarding the role of the first-generation (TIND) and second-generation (iTIND) devices for the management of BPH with LUTS, especially focusing on follow-up of functional outcomes.Evidence AcquisitionPubMed, Embase, and the Cochrane Central Register of Controlled Trials were screened for clinical trials on this topic.Evidence SynthesisLiterature evidences regarding implantation of TIND and iTIND for PBH with LUTS are limited. There are only three studies available, one with a medium-term follow-up. The results of these studies suggested that both the TIND and iTIND implantations are safe, effective, and well-tolerated procedures, allowing spare ejaculation in sexually active patients.ConclusionsCurrent evidences emphasize that the temporary implantable nitinol devices are promising alternatives to the standard minimally invasive surgical options for BPH-related LUTS. Further studies are needed to confirm the effectiveness over a long-term follow-up.

热门文献